In a recent discussion, Professor Tim Meyer highlighted the importance of multidisciplinary care in liver cancer treatment. As systemic therapies evolve, including combinations of tyrosine kinase inhibitors and immunotherapy, there’s been substantial progress in response rates and survival outcomes. Professor Meyer emphasized the need for further research to refine adjuvant therapies and address gaps in precision oncology for hepatocellular carcinoma.
Discover how these advancements are reshaping liver cancer care and encouraging new research!
